Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported a 44% jump in Ryoncil net revenue to US$28 million and an 85% improvement in net operating cash spend for the first fiscal quarter.

Happy healthcare workers in a lab.

Image source: Getty Images

What did Mesoblast report?

  • Net revenue from Ryoncil sales rose 44% to US$28 million (Q1 FY25: US$19 million)
  • Net operating cash spend improved 85% to just US$2.3 million (prior period: US$14.9 million)
  • Strong cash position: US$99 million at 30 September 2026
  • Record new patient starts in September after seasonal July/August slowdown

What else do investors need to know?

Mesoblast attributes its revenue growth and improved cash position to greater penetration and adoption of Ryoncil across 54 onboarded treatment sites. Ryoncil is the first and only FDA-approved mesenchymal stromal cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease.

The company is also focusing on disciplined capital management to support its commercial manufacturing and late-stage clinical programs. All reported results are preliminary and subject to audit.

What's next for Mesoblast?

Looking ahead, Mesoblast plans to expand the reach of Ryoncil, further increasing adoption among eligible hospitals and clinics. The company is also progressing additional pipeline products targeting inflammatory diseases and is strengthening commercial partnerships overseas.

Disciplined capital use and investment in late-stage clinical trials remain priorities. Management is focused on building sustainable growth while maintaining strong cash reserves.

Mesoblast share price snapshot

Over the past 12 months, Mesoblast shares have declined 29%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »